Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Fig. 4

Analysis of correlation between proportions of Tregs and prognosis. a The changes of percentages of Treg cells in patients with short or long-term courses of immunotherapy, compared to pre-therapy group. The dot-bar represented patients enrolled in immunotherapy more than three cycles. b The changes of percentages of Treg cells in patients with immunotherapy alone or in combination with other adjuvant therapeutic strategies, compared to pre-therapy group. The diagonal-bar represented patients recruited during our immunotherapy combined with other adjuvant therapies. *Statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001). c The heatmap showed the clinical values of six serum tumor markers for each type of tumor. Each color represented the level of tumor markers in serum, and the color legend was shown at the bottom of the heatmap. d The changes of immune indicators including CD3+, CD3+ CD4+, CD3+ CD8+, CD3+ CD56+ and Treg in 14 patients who were with negative for all serological indexes. *Statistically significant differences (*p < 0.05)

Back to article page